

CytomX Therapeutics, Inc.
Form SC 13G
February 10, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.)*

CytomX Therapeutics, Inc.
(Name of Issuer)

COMMON STOCK, \$0.00001 PAR VALUE PER SHARE
(Title of Class of Securities)

23284F105
(CUSIP Number)

December 31, 2015
(Date of Event Which Requires Filing of this Statement)

Edgar Filing: CytomX Therapeutics, Inc. - Form SC 13G

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 23284F105

Page 2 of 11 Pages

1. NAMES OF REPORTING PERSONS

Third Rock Ventures, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES

0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,670,348

7. SOLE DISPOSITIVE POWER

EACH

REPORTING

PERSON

0

8. SHARED DISPOSITIVE POWER

WITH

8,670,348

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,670,348

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ..
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
12. 24.1% (1)
TYPE OF REPORTING PERSON

PN

- (1) The percent of class was calculated based on 36,024,292 shares of common stock issued and outstanding as of November 19, 2015, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 23, 2015.

SCHEDULE 13G

CUSIP No. 23284F105

Page 3 of 11 Pages

1. NAMES OF REPORTING PERSONS

Third Rock Ventures GP, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES

0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,670,348

7. SOLE DISPOSITIVE POWER

EACH

REPORTING

PERSON

0

8. SHARED DISPOSITIVE POWER

WITH

8,670,348

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,670,348

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ..

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 24.1% (1)
TYPE OF REPORTING PERSON

PN

SCHEDULE 13G

CUSIP No. 23284F105

Page 4 of 11 Pages

1. NAMES OF REPORTING PERSONS

2. **TRV GP, LLC**
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

NUMBER OF

SHARES

0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,670,348

7. SOLE DISPOSITIVE POWER

EACH

REPORTING

PERSON

0

8. SHARED DISPOSITIVE POWER

WITH

8,670,348

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,670,348

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ..

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 24.1% (1)
TYPE OF REPORTING PERSON

OO

SCHEDULE 13G

CUSIP No. 23284F105

Page 5 of 11 Pages

1. NAMES OF REPORTING PERSONS

Mark Levin

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

NUMBER OF

SHARES

0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,670,348

7. SOLE DISPOSITIVE POWER

EACH

REPORTING

PERSON

0

8. SHARED DISPOSITIVE POWER

WITH

8,670,348

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,670,348

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ..

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 24.1% (1)
TYPE OF REPORTING PERSON

IN

SCHEDULE 13G

CUSIP No. 23284F105

Page 6 of 11 Pages

1. NAMES OF REPORTING PERSONS

Kevin P. Starr

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

NUMBER OF

SHARES

0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,670,348

7. SOLE DISPOSITIVE POWER

EACH

REPORTING

PERSON

0

8. SHARED DISPOSITIVE POWER

WITH

8,670,348

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,670,348

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 24.1% (1)
TYPE OF REPORTING PERSON

IN

SCHEDULE 13G

CUSIP No. 23284F105

Page 7 of 11 Pages

1. NAMES OF REPORTING PERSONS

Robert I. Tepper

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) (b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

NUMBER OF

SHARES

0

6. SHARED VOTING POWER

BENEFICIALLY

OWNED BY

8,670,348

7. SOLE DISPOSITIVE POWER

EACH

REPORTING

PERSON

0

8. SHARED DISPOSITIVE POWER

WITH

8,670,348

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

8,670,348

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ..

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12. 24.1% (1)
TYPE OF REPORTING PERSON

IN

SCHEDULE 13G

CUSIP No. 23284F105

Page 8 of 11 Pages

Item 1. Issuer

- (a) Name of Issuer:
CytomX Therapeutics, Inc. (the **Issuer**)
- (b) Address of Issuer's Principal Executive Offices:
343 Oyster Point Blvd, Suite 100

South San Francisco, CA 94080

Item 2. Filing Person

- (a) (c) Name of Persons Filing; Address; Citizenship:
- (i) Third Rock Ventures, L.P. (**TRV**);
 - (ii) Third Rock Ventures GP, L.P. (**TRV GP**), which is the sole general partner of TRV;
 - (iii) TRV GP, LLC (**TRV GP LLC**), which is the sole general partner of TRV GP;
 - (iv) Mark Levin (**Levin**), a managing member of TRV GP LLC;
 - (v) Kevin P. Starr (**Starr**), a managing member of TRV GP LLC; and
 - (vi) Robert I. Tepper (**Tepper**, and collectively with TRV, TRV GP, TRV GP LLC, Levin and Starr, the **Reporting Persons**), a managing member of TRV GP LLC.

The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 29 Newbury Street, 3rd Floor, Boston, MA 02116.

Each of TRV and TRV GP is a Delaware limited partnership. TRV GP LLC is a Delaware limited liability company. Levin, Tepper, and Starr are United States citizens.

- (d) Title of Class of Securities:
Common stock, \$0.00001 par value per share, (the **Common Stock**).
- (e) CUSIP Number:

23284F105

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Act;
- (b) Bank as defined in Section 3(a)(6) of the Act;

Edgar Filing: CytomX Therapeutics, Inc. - Form SC 13G

- (c) " Insurance company as defined in Section 3(a)(19) of the Act;
- (d) " Investment company registered under Section 8 of the Investment Company Act of 1940;
- (e) " An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) " An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) " A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) " A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) " A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j) " A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
- (k) " Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

SCHEDULE 13G
CUSIP No. 23284F105**Page 9 of 11 Pages**

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

(a) and (b) Amount beneficially owned:

- (i) TRV directly owns 8,670,348 shares of Common Stock (the **Shares**), which represents approximately 24.1% of the outstanding shares of Common Stock.
- (ii) TRV GP is the general partner of TRV and may be deemed to beneficially own the Shares.
- (iii) TRV GP LLC is the general partner of TRV GP and may be deemed to beneficially own the Shares.
- (iv) As a managing member of TRV GP LLC, Levin may be deemed to beneficially own the Shares.
- (v) As a managing member of TRV GP LLC, Tepper may be deemed to beneficially own the Shares.
- (vi) As a managing member of TRV GP LLC, Starr may be deemed to beneficially own the Shares.

(c) Number of shares as to which such person has:

Reporting Person	Number of Shares of Common Stock			
	(i)	(ii)	(iii)	(iv)
TRV		8,670,348		8,670,348
TRV GP		8,670,348		8,670,348
TRV GP LLC		8,670,348		8,670,348
Levin		8,670,348		8,670,348
Starr		8,670,348		8,670,348
Tepper		8,670,348		8,670,348

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of

(iv) Shared power to dispose or to direct the disposition of

The percent of class was calculated based on 36,024,292 shares of common stock issued and outstanding as of November 19, 2015, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 23, 2015.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

SCHEDULE 13G

CUSIP No. 23284F105

Page 10 of 11 Pages

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

SCHEDULE 13G

CUSIP No. 23284F105

Page 11 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2016

THIRD ROCK VENTURES, L.P.

By: THIRD ROCK VENTURES GP, L.P.,
General Partner

By: TRV GP, LLC,
General Partner

By: /s/ Kevin Gillis
Kevin Gillis
Chief Financial Officer

THIRD ROCK VENTURES GP, L.P.

By: TRV GP, LLC,
General Partner

By: /s/ Kevin Gillis
Kevin Gillis
Chief Financial Officer

TRV GP, LLC

By: /s/ Kevin Gillis
Kevin Gillis
Chief Financial Officer

MARK LEVIN

/s/ Kevin Gillis, As attorney-in-fact
Mark Levin

KEVIN P. STARR

/s/ Kevin Gillis, As attorney-in-fact
Kevin P. Starr

ROBERT I. TEPPER

/s/ Kevin Gillis, As attorney-in-fact
Robert I. Tepper